McKesson (MCK) Q4 2024 Earnings
McKesson reported Q4 2024 revenue of $95.3B, missed analyst consensus of $96.1B by $760.8M. Diluted EPS came in at $8.03, missed the $8.60 consensus by $0.57. McKesson reports across 4 business segments, led by U.S. Pharmaceutical, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS).
Financial Snapshot
Trailing eight quarters through Q4 2024
Q4 2024 Earnings FAQ
Common questions about McKesson's Q4 2024 earnings report.
McKesson (MCK) reported Q4 2024 earnings on February 5, 2025 after market close.
McKesson reported revenue of $95.3B and diluted EPS of $8.03 for Q4 2024.
Revenue missed the consensus estimate of $96.1B by $760.8M. EPS missed the consensus estimate of $8.60 by $0.57.
You can read the 10-Q periodic report (0000927653-25-000014) directly on SEC EDGAR. The filing index links above go to sec.gov.